Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Last trade$26.71
Day change-$0.095 (-0.35%)
Day range$26.46 – $27.94
Volume3,075,016
Market cap$3.42B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.42B
Price / earnings
—
Price / book
5.81×
Price / sales
—
EV / sales
—
EV / EBITDA
-4.61×
Profitability
Earnings per share
-$4.92
Return on assets
-64.19%
Return on equity
-106.56%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.43×
Current ratio
7.27×
Quick ratio
7.27×
Cash ratio
5.06×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$462.63M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VKTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$20.31M
$16.84M
$13.98M
$11.28M
$8.61M
$14.42M
$14.08M
$15.25M
Research and development
$166.8M
$115.75M
$150.15M
$153.46M
$89.95M
$60.15M
$41.39M
$30.99M
Total operating expenses
$187.11M
$132.6M
$164.13M
$164.74M
$98.56M
$74.57M
$55.47M
$46.24M
Operating income
-$187.11M
-$132.6M
-$164.13M
-$164.74M
-$98.56M
-$74.57M
-$55.47M
-$46.24M
Interest expense
-$88K
$0
$0
$56K
$0
$0
$0
$70K
Income before taxes
-$183.19M
-$128.02M
-$158.33M
-$157.66M
-$90.79M
-$65.56M
-$45.63M
-$35.42M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$183.19M
-$128.02M
-$158.33M
-$157.66M
-$90.79M
-$65.56M
-$45.63M
-$35.42M
Net income attributable to common shareholders
-$183.19M
-$128.02M
-$158.33M
-$157.66M
-$90.79M
-$65.56M
-$45.63M
-$35.42M
EBITDA
-$187.11M
-$132.6M
-$164.13M
-$164.74M
-$98.56M
-$74.57M
-$55.47M
-$46.24M
Basic earnings per share
-$1.55
-$1.10
-$1.37
-$1.38
-$0.81
-$0.58
-$0.41
-$0.32
Diluted earnings per share
-$1.55
-$1.10
-$1.37
-$1.38
-$0.81
-$0.58
-$0.41
-$0.32
Recent news
Company coverage with links to the original publishers.
Viking Therapeutics announced initiation of phase 3 trials for its oral weight-loss tablet VK2735 and demonstrated that patients maintained significant weight loss with less frequent dosing schedules (biweekly or monthly). The company raised $575 million in capital, bringing total cash to $960 million, positioning it well for commercial launch preparation. The dosing flexibility offers a structural advantage over current competitors in the obesity drug market.
Viking Therapeutics is conducting phase 3 trials for its obesity drug VK2735 in both injectable and oral forms. The oral formulation could expand the addressable market through a dual-dosing strategy. With conservative assumptions of 50% phase 3 success rate and 10% market share of tirzepatide's peak sales, Viking's stock could reach $110 per share by 2028, making a $10,000 investment worth up to $47,800.
Eli Lilly raised its 2026 sales forecast to $91-92 billion, driven by strong Zepbound weight-loss drug sales. While smaller competitor Viking Therapeutics shows promise with its VK2735 candidate demonstrating encouraging clinical trial results, Eli Lilly's diversified pipeline and market leadership position it well to withstand competition. Viking offers high upside potential but carries significant clinical and regulatory risks.
DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.
Novo's newly launched Wegovy oral pill generated DKK 5.4 billion in Q3 2026 sales with 3.6 million U.S. prescriptions, prompting the company to raise its 2026 growth outlook. However, the company faces intense competition from Eli Lilly's surging Mounjaro and Zepbound sales, as well as emerging competitors like Viking Therapeutics and Structure Therapeutics developing alternative GLP-1 therapies. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.